EPHX2 and prostate adenocarcinoma: In this study, we identified five novel genes with high CNV in PRAD by WGCNA (CCNE2, RHPN1, EZH2, TONSL, and EPHX2) along with two hypermethylated genes (FMOD and SLC7A4) that were significantly correlated with the prognosis of patients with PRAD and may thus be clinically useful biomarkers.